Viridian Therapeutics, Inc. VRDN Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$342.6M-26.9% | -$269.95M-13.6% | -$237.73M-83.0% | -$129.87M-63.5% | ||
| $460K-14.8% | $540K+3.4% | $522K+105% | $255K+113% | ||
| $44.3M+5.1% | $42.15M-37.3% | $67.17M+240% | $19.77M+36.6% | ||
| —— | -$73K+99.4% | -$12.04M-204% | $11.52M— | ||
| —— | $21.34M— | —— | —— | ||
| —— | —— | —— | $3.34M— | ||
| -$157K+74.7% | -$620K+20.0% | -$775K— | $0— | ||
| -$276.39M-19.0% | -$232.32M-26.1% | -$184.17M-96.3% | -$93.84M-71.9% | ||
| $495K-3.1% | $511K-43.1% | $898K+12.7% | $797K+136% | ||
| $579.28M-16.7% | $695.07M+70.4% | $407.88M— | —— | ||
| $542.21M+16.1% | $466.93M+48.5% | $314.53M+189% | $108.94M-5.2% | ||
| -$37.56M— | —— | -$94.25M+18.1% | -$115.13M-55.0% | ||
| $65.03M— | —— | $15.26M-94.8% | $291.87M+155% | ||
| $478K— | $0-100% | $514K+15.2% | $446K— | ||
| $426.74M-6.8% | $457.74M+103% | $225.67M-30.0% | $322.24M+157% | ||
| $112.79M+3,589% | -$3.23M— | —— | —— | ||
| $2.15M+18.1% | $1.82M+105% | $886K— | —— | ||
| $6.76M-56.8% | $15.66M+36.2% | $11.49M+5,371% | $210K+122% | ||
| —— | $0— | $0— | —— | ||
| $1.75M— | $0— | $0— | —— | ||
| —— | —— | —— | $3.34M— | ||
| —— | -$620K+20.0% | -$775K— | $0— | ||
| —— | —— | $317K— | —— | ||
| $542.21M+16.1% | $466.93M+48.5% | $314.53M+189% | $108.94M— | ||
| $4.98M— | $0— | $0— | —— | ||
| $478K— | $0-100% | $514K+15.2% | $446K— | ||
| —— | —— | —— | —— | ||
| $55M— | $0— | $0— | —— | ||
| —— | $674K— | —— | —— | ||
| —— | $0— | —— | —— | ||
| $0-100% | $837K+30.6% | $641K+43.1% | $448K— | ||
| -$276.89M-18.9% | -$232.83M-25.8% | -$185.07M-95.6% | -$94.64M-72.3% | ||
| -$276.89M-18.9% | -$232.83M-25.8% | -$185.07M-95.6% | -$94.64M-72.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viridian Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.